New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 21, 2014
09:42 EDTVRXValeant to sell Precision's assets related to two acne treatments
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Valeant Pharmaceuticals International's proposed $475M acquisition of Precision Dermatology. would likely be anticompetitive. Under the order, Valeant has agreed to sell Precision’s assets related to two acne treatments – Tretin-X, its branded single-agent topical tretinoin, and generic Retin-A – within 10 days of consummating the transaction. According to the FTC’s complaint, first announced in July, Valeant’s acquisition of Precision as originally proposed would likely reduce competition in the market for branded and generic single-agent topical tretinoins, and in a separate market for generic Retin-A. Reference Link
News For VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
07:29 EDTVRXValeant selected as lead bidder to acquire Dendreon, Provenge for $296M
Subscribe for More Information
05:20 EDTVRXDendreon reaches agreement for Valeant to serve as 'stalking horse bidder'
Subscribe for More Information
January 22, 2015
05:57 EDTVRXActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
12:30 EDTVRXGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use